Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + toripalimab + albumin-bound paclitaxel + radiotherapy for first-line treatment of advanced esophageal squamous cell carcinoma
ChiCTR2600116673Phase 2Completed
- Sponsor
- Department of Radiation Oncology, the First Medical Center, Chinese People's Liberation Army General Hospital
- Start
- Jan 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib, toripalimab and paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Department of Radiation Oncology, the First Medical Center, Chinese People's Liberation Army General Hospital. Primary endpoint: Progression-free survival time. Started Jan 2026; status: completed.
02
Drugs
surufatinibtoripalimabpaclitaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600116673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116673.